Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04671693
Other study ID # PASCA
Secondary ID 2020-A01130-39
Status Recruiting
Phase N/A
First received
Last updated
Start date December 24, 2020
Est. completion date April 24, 2028

Study information

Verified date August 2023
Source Centre Leon Berard
Contact Romain BUONO, PharmD, MPH
Phone +33469856358
Email romain.buono@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program. METHOD: PASCA is a single-center, interventional cohort study of adult patients who received at least chemotherapy and with a complete remission to a testicular germ cell tumor, primary non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four assessment visits will be scheduled at 1 month (T1), 6 months (T2), 24 months (T3) and 60 months (T4) after completion of treatment. During these visits, 22 complications will be screened and follow-up care will be systematically offered to the health professional concerned by the complication in case of a positive result. The screening will contain the following elements: screening self-questionnaires, quality of life questionnaire, 12 biological parameters, a urinalysis evaluating hematuria, proteinuria, and leukocyturia, a spirometry, an electrocardiogram, 5 tests evaluating physical condition, vital signs and the perimetric measurement between both arms. DISCUSSION: This systematic screening could highlight a number of complications occurring after cancer treatments. Sub-clinical abnormalities and new risk factors could also be identified. This new organization of care could improve the quality of life of adult cancer survivors.


Recruitment information / eligibility

Status Recruiting
Enrollment 858
Est. completion date April 24, 2028
Est. primary completion date January 24, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old and = 65 years old. 2. Follow-up at the Léon Bérard center 3. Treated by chemotherapy for one of the following pathologies, and confirmed by the reference diagnostic technique : - acute myeloid leukemia; - Hodgkin's lymphoma; - aggressive non-Hodgkin's lymphoma; - primary non-metastatic invasive breast carcinoma; - testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin, etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP (etoposide, ifosfamide, cisplatin) received; - high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma. 4. As a complete response at the end of treatment consultation. If end-of-treatment evaluation is not available at the time of inclusion: as an assumed complete response in the opinion of the investigator based on the previous assessment of response. 5. Whose capacity to practice an adapted physical activity will have been certified by a medical certificate issued by the investigating physician, the general practitioner or the referring physician. 6. Able to understand, read and write French. 7. Available and willing to participate in the project throughout the duration of the study. 8. Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire 9. Affiliated with a health insurance plan. 10. Having declared an attending physician. 11. Having signed and dated the informed consent. Exclusion Criteria: 1. With a history of malignancy other than basal cell skin cancer. 2. Cannot be followed for medical, social, family, geographical or psychological reasons for the duration of the study. 3. Participating in other studies that could impact on the evaluation of the judgement criteria. 4. Deprived of liberty by judicial or administrative decision.

Study Design


Intervention

Other:
PASCA intervention
At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted. Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology.

Locations

Country Name City State
France Centre Leon Berard Lyon

Sponsors (8)

Lead Sponsor Collaborator
Centre Leon Berard Biogaran, Fédération Leucémie Espoir, Fondation Apicil, Le défi Anthony, Malakoff-Humanis, Novartis, Roche Pharma AG

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of social precariousness Diagnosed by a social worker Month 1
Primary Change from Baseline return to work issues incidence at 60 months Diagnosed by a social worker Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline cognitive problems incidence at 60 months Diagnosed by a neurologist Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline anxiety crises incidence at 60 months Diagnosed by a psychologist or psychiatrist Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline depressive events incidence at 60 months Questionnaire "HADS-D" (Hospital Anxiety and Depression scale) Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline chronic fatigue incidence at 60 months Questionnaire "MFI-20" (Multidimensional Fatigue Inventory) Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline physical deconditioning incidence at 60 months A value below the lower limit on at least two of the following physical tests
Six-Minute Walk Test (6MWT) (meters)
Hand Grip Strength Test (Kg)
Five Times Sit to Stand Test (number)
Flamingo Test (sec)
Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline overweight/obesity incidence at 60 months BMI
Waist circumference
Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline chronic pain incidence at 60 months Duration of pain
Questionnaire "DN4" (Douleur Neuropathique en 4 questions)
Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline dermatological disorders incidence at 60 months Common Terminology Criteria for Adverse Events (CTCAE) v5 Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline gastrointestinal disorders incidence at 60 months Common Terminology Criteria for Adverse Events (CTCAE) v5 Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline sexual disorders incidence at 60 months Questionnaire "Sexualité VICAN5" Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline hypogonadism incidence at 60 months Presence of clinical signs as defined by the International Society for Sexual Medicine
A value below the lower limit on at least one of the following blood assay:
level of total testosterone
level of bioavailable testosterone
Month 1, Month 6, Month 24, Month 60
Primary Change from 24 months premature ovarian failure incidence at 60 months level of Follicle stimulating hormone
level of estradiol
Month 24, Month 60
Primary Change from Baseline osteoporosis incidence at 60 months T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline chronic kidney failure incidence at 60 months Diagnosed on the basis of 2 blood tests within 3 months using the same technique showing a decrease in GFR to < 60ml/min/1.73m2, estimated from creatinine levels using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009), albuminuria or proteinuria positive, hematuria, leukocyturia > 10/mm3, or morphological abnormality on renal ultrasound. Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline heart failure incidence at 60 months Diagnosed by a cardiologist with an echocardiography performing the Left Ventricular Ejection Fraction (LVEF) estimate Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline coronary heart disease incidence at 60 months Diagnosed by a cardiologist conducting at least an interrogation with clinical examination, an estimation of pre-test probability of coronary artery disease Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline respiratory failure incidence at 60 months Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Total lung capacity
Diffusing Capacity Of The Lungs For Carbon Monoxide
Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline hypothyroidism incidence at 60 months level of thyroid-stimulating hormone
level of total thyroxine
Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline lymphedema incidence at 60 months Diagnosed by a vascular physician with a perimetric measurement of arms and forearms Month 1, Month 6, Month 24, Month 60
Primary Change from Baseline second primary cancers incidence at 60 months Pathology report recorded in the patient file. Month 1, Month 6, Month 24, Month 60
Secondary Evaluate the PASCA program: referrals made through the network Number of referrals made through the network (attending physicians, specialist physicians, supportive care services or other health professionals) Month 6, Month 24, Month 60
Secondary Evaluate the PASCA program: time between patient referral and completion of the first consultation Average time (days) between patient referral and completion of the first consultation Month 6, Month 24, Month 60
Secondary Evaluate the PASCA program: patient characteristics Comorbidities at diagnosis
Tumor classification
cytogenetics mutations
types and doses of each cancer treatments
ratio of the number of patients included / number of eligible patients
Month 1, Month 6, Month 24, Month 60
Secondary Evaluation of the impact of program adherence on the evolution of the number of complications detected over time Measurement of the association between program adherence rate and the number of complications detected over time Month 6, Month 24, Month 60
Secondary Evaluation of the impact of program adherence on quality of life. Measurement of the association between program adherence rate and the overall score on the secondary dimensions of quality of life. Month 6, Month 24, Month 60
Secondary Description of the PASCA network : characteristics of health professionals sensitive to the post-treatment issues. number of health professionals affiliated with the network
type of health professionals affiliated with the network
distribution over the Auvergne-Rhône-Alpes region according to medical speciality and department
Month 6, Month 24, Month 60
Secondary Identification of risk factors associated with complications occurring during follow-up. Measurement of the association between suspected risk factors and the occurrence of a type of complication, during the duration of follow-up. Month 1, Month 6, Month 24, Month 60
Secondary Description of the Global Longitudinal Strain Evolution of the Global Longitudinal Strain in absolute value, relative to a later value Month 6, Month 24, Month 60
Secondary Description of the Left Ventricular Ejection Fraction Evolution of the Left Ventricular Ejection Fraction relative to a later value Month 6, Month 24, Month 60
Secondary Description of the troponin I level Evolution of the troponin I level relative to a later value Month 6, Month 24, Month 60
Secondary Description of the Glomerular Filtration Rate Evolution of the Glomerular Filtration Rate estimated by the CKD-EPI equation relative to a later value Month 6, Month 24, Month 60
Secondary Description of spirometry values Evolution of spirometry values relative to later values :
Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Month 6, Month 24, Month 60
Secondary Incidence of diabetes mellitus Level of fasting blood glucose Month 6, Month 24, Month 60
Secondary Incidence of untreated high blood pressure Measure of systolic blood pressure Month 6, Month 24, Month 60
Secondary Incidence of hypertriglyceridemia Level of triglyceridemia Month 6, Month 24, Month 60
Secondary Incidence of hyper-LDL-cholesterolemia Level of LDL-cholesterolemia Month 6, Month 24, Month 60
Secondary Incidence of low level of physical activity Questionnaire "Godin-Shephard Leisure-Time Physical Activity" Month 6, Month 24, Month 60
Secondary Incidence of insufficiency / deficiency of 25(OH) vitamin D (D2+D3) Level of 25(OH) vitamin D (D2+D3) Month 6, Month 24, Month 60
Secondary Description of carcinogenic products consumption (tobacco, alcohol, cannabis) Number of packages years
Questionnaire "DETA-Cage"
Month 1, Month 6, Month 24, Month 60
Secondary Evaluation of the Progression-free survival Evaluation of the Progression-free survival Month 6, Month 24, Month 60
Secondary Evaluation of the Survival without an increase in the number of complications, among those studied Evaluation of the Survival without an increase in the number of complications, among those studied Month 6, Month 24, Month 60
Secondary Evaluation of the event-free survival Evaluation of the event-free survival Month 6, Month 24, Month 60
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2